Skip to main content
. Author manuscript; available in PMC: 2019 Jul 15.
Published in final edited form as: Biomaterials. 2019 Mar 21;206:13–24. doi: 10.1016/j.biomaterials.2019.03.026

Fig. 7. In vivo antitumor activity of LProd.

Fig. 7.

(A) Schematic illustration of therapeutic process. Athymic nude mice (Balb/c) bearing HCT116 p53+/+ were established and randomly divided into five groups (n = 5/group). Ten days following inoculation, mice were treated by the intraperitoneal injection every other day for 6 times with PBS, 1.5 mg/kg doxorubicin, 1.5 mg/kg PMI, 1.5 mg/kg Lrod, 1.5 mg/kg LProd or 1.5 mg/kg LPparticle, respectively. (B) Tumor growth curves in nude mice subcutaneously inoculated with 1 × 106 HCT116 cells into the right flank. The indicated treatments were administered every other day. Data are presented as mean ± s. e. (n = 5). (C) The weight of xenograft tumors from mice with the indicated treatments. Representative H&E (D) and TUNEL (E) stained images of xenograft tumors from mice with the indicated treatments (scale bar: 50 μm). P values were calculated by t-test (*, p < 0.05; **, p < 0.01; ***, p < 0.001).